# Tucatinib Continuation Study

> **NCT07768358** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Pfizer** · enrollment: 175 (estimated)

## Conditions studied

- HER2-positive Breast Cancer
- Cervical Cancer
- Biliary Tract Neoplasms
- Urothelial Cancer
- Advanced Non-Small Cell Lung Cancer
- Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
- Colorectal Cancer

## Interventions

- **DRUG:** tucatinib

## Key facts

- **NCT ID:** NCT07768358
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-06
- **Primary completion:** 2032-03-13
- **Final completion:** 2032-03-13
- **Target enrollment:** 175 (ESTIMATED)
- **Last updated:** 2026-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07768358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07768358, "Tucatinib Continuation Study". Retrieved via MORVS 2026-11-22 from https://api.morvs.ai/clinical/NCT07768358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
